The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Cited by
Sorted by citations
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodríguez-Torres, M. D. P., Acosta‐Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 7,085
DLS and zeta potential – What they are and what they are not?
Bhattacharjee, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.017 · Cited by 4,702
“, macromolecules [16], peptides [17]) and release at target sites (e.”
BackgroundNear-infrared fluorophores for biomedical imaging
Hong, G., Antaris, A. L., & Dai, H. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0010 · Cited by 3,048
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
Liu, Y., Bhattarai, P., Dai, Z., & Chen, X. S. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00618k · Cited by 2,936
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
Cui, X., Ruan, Q., Zhuo, X., Xia, X., Hu, J., Fu, R., Li, Y., Wang, J., & Xu, H. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00159 · Cited by 2,006
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
Li, S., Jiang, Q., Liu, S., Zhang, Y., Tian, Y., Song, C., Wang, J., Zou, Y., Anderson, G. J., Han, J.-Y., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4071 · Cited by 1,481
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,279
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
“Compared with liposome nanomaterials, metal nanomaterials, and polymer nanomaterials, exosomes as carriers can overcome the shortcomings of poor bioavailability and reduce non-targeted cytotoxicity and immunogenicity.(144,145) And exosomes contain transmembrane and membrane anchoring proteins, which enhance endocytosi…”
BackgroundPolymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,279
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“M the LNP; and (4) a polyethylene glycol (PEG)lipid to lend the nanoparticle a hydrating layer, improve colloidal stability, and reduce protein absorption.(19,20)”
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,145
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,113
A bioorthogonal system reveals antitumour immune function of pyroptosis
Wang, Q., Wang, Y., Ding, J., Wang, C., Zhou, X., Gao, W., Huang, H., Shao, F., & Liu, Z. (2020) · Nature · doi:10.1038/s41586-020-2079-1 · Cited by 1,119
The Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
“Most of nanoplatforms will not succeed in clinics if the biological barriers faced by the nanoparticles are not conquered [184].”
BackgroundRational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,068
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
“Deformability and degradability are also important for a smarter drug to be released in the right environmental condition to execute a tumor-killing effect once it enters the tumor tissue [39,40].”
BackgroundSmart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
“Interstitial fluid pressure (IFP) is another barrier in the way of successful accumulation of drug-loaded nanocarriers in the solid tumor [172,173]; however, efficient modifications of nanocarriers can overcome many biological barriers, including IFP and the RES [174].”
BackgroundInfluentialEmerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. U. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 1,005
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 985
“internalization via caveolin-dependent endocytosis and typically use nanoparticle surface ligands such as folic acid, albumin, and cholesterol [19].”
BackgroundCancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
“This phenomenon, known as the enhanced permeability and retention (EPR) effect, has been utilized for passive targeting of nanoparticles to tumor tissue, but deeper penetration into the tumor is frequently restricted due to heterogeneity of the tumor microenvironment [46].”
BackgroundGold Nanoparticles for Photothermal Cancer Therapy
Vines, J. B., Yoon, J.-H., Ryu, N.-E., Lim, D.-J., & Park, H. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00167 · Cited by 910
“(<8 nm) are capable of passing through the renal filtration system whereas larger GNPs (>10 nm) are more likely to remain in the blood stream, and thus accumulate in the liver and kidney (Bartneck et al., 2012; Zhang et al., 2012; Blanco et al., 2015).”
BackgroundNanomedicine in cancer therapy
Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., & Gong, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01536-y · Cited by 986
“58,59 Furthermore, the surface charge has been found to exert in fl uence on the intratumoral distribution of nanoparticles via the EPR mechanism.”
BackgroundIn vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Engineering Macrophages for Cancer Immunotherapy and Drug Delivery
Xia, Y., Rao, L., Yao, H., Wang, Z., Ning, P., & Chen, X. (2020) · Advanced Materials · doi:10.1002/adma.202002054 · Cited by 949
Photosensitizers with Aggregation‐Induced Emission: Materials and Biomedical Applications
Hu, F., Xu, S., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201801350 · Cited by 859
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 882
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.01.066 · Cited by 871
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 858
“While the natural tendency of M2 macrophages to more readily internalize nanoparticles could be beneficial for designing TAM-targeted therapy, the resident macrophages’ penchant for internalizing nanoparticles is still an important challenge in developing TAM-targeted therapies [185][186][181][187].”
Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
Mi, P. (2020) · Theranostics · doi:10.7150/thno.38069 · Cited by 874
Enzyme-activatable polymer–drug conjugate augments tumour penetration and treatment efficacy
Zhou, Q., Shao, S., Wang, J., Xu, C., Xiang, J., Piao, Y., Zhou, Z., Yu, Q., Tang, J., Liu, X., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0485-z · Cited by 831
Role of nanoparticle size, shape and surface chemistry in oral drug delivery
Banerjee, A., Qi, J., Gogoi, R., Wong, J., & Mitragotri, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.051 · Cited by 777
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 767
Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control
Liu, Y., Shi, L., Su, L., van der Mei, H. C., Jutte, P. C., Ren, Y., & Busscher, H. J. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00807d · Cited by 737
Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model
Zhang, Y., Tan, H., Daniels, J. D., Zandkarimi, F., Liu, H., Brown, L. M., Uchida, K., O’Connor, O. A., & Stockwell, B. R. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.01.008 · Cited by 739
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy
Li, H., Du, J., Du, X., Xu, C., Sun, C.-Y., Wang, H., Cao, Z.-T., Yang, X., Zhu, Y.-H., Nie, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522080113 · Cited by 726
“Achieving this goal is vitally important because these barriers are interconnected, and simply overcoming one individual barrier is not adequate to produce proper therapeutic outcomes (42, 47).”
BackgroundAdvances in Magnetic Nanoparticles for Biomedical Applications
Cardoso, V. F., Francesko, A., Ribeiro, C., Bañobre‐López, M., Martins, P., & Lanceros-Méndez, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700845 · Cited by 738
The Impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery
Corbo, C., Molinaro, R., Parodi, A., Furman, N. E. T., Salvatore, F., & Tasciotti, E. (2015) · Nanomedicine · doi:10.2217/nnm.15.188 · Cited by 721
Li, Z., Lai, X., Fu, S., Ren, L. F., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 704
Application of zirconium MOFs in drug delivery and biomedicine
Lázaro, I. A., & Forgan, R. S. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.09.009 · Cited by 693
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos‐Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi‐Fainaro, R., Florindo, H. F., & Vicent, M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 715
“Targeted and non-targeted nanomedicines can improve the stability and solubility of associated active payloads, promote transport across membranes, and prolong circulation times to increase safety and efficacy [2, 3].”
BackgroundSafety Assessment of Graphene-Based Materials: Focus on Human Health and the Environment
Fadeel, B., Bussy, C., Merino, S., Vázquez, E., Emmanuel Flahaut, B., Mouchet, F., Evariste, L., Gauthier, L., Koivisto, A. J., Vogel, U. B., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04758 · Cited by 693
Form Follows Function: Nanoparticle Shape and Its Implications for Nanomedicine
Kinnear, C., Moore, T. L., Rodríguez‐Lorenzo, L., Rothen‐Rutishauser, B., & Petri‐Fink, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00194 · Cited by 685
Xi, D., Xiao, M. W., Cao, J., Zhao, L., Xu, N., Long, S., Fan, J., Shao, K., Sun, W. C., Yan, X., et al. (2020) · Advanced Materials · doi:10.1002/adma.201907855 · Cited by 668
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simón‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 661
Quantum Dots in Biomedical Applications
Wagner, A. M., Knipe, J. M., Orive, G., & Peppas, N. A. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.022 · Cited by 659
Cheng, G., Huang, Q., Liu, C., Kwong, C. H. T., Yue, L., Wan, J., Lee, S. M., & Wang, R. (2020) · Nature Communications · doi:10.1038/s41467-020-16439-7 · Cited by 635
The Endosomal Escape of Nanoparticles: Toward More Efficient Cellular Delivery
Smith, S. A., FitzGerald, L. I., Johnston, A. P. R., & Such, G. K. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00732 · Cited by 638
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 624
Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy
Meng, H., Liu, H., Kuai, H., Peng, R., Mo, L., & Zhang, X. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00645g · Cited by 616
Plasmonic Heating of Nanostructures
Jauffred, L., Samadi, A., Klingberg, H., Bendix, P. M., & Oddershede, L. B. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00738 · Cited by 612
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszyński, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 619
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 605
Glomerular barrier behaves as an atomically precise bandpass filter in a sub-nanometre regime
Du, B., Jiang, X., Das, A., Zhou, Q., Yu, M., Jin, R. M., & Zheng, J. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.170 · Cited by 595
Safe Nanoparticles: Are We There Yet?
Najahi‐Missaoui, W., Arnold, R. D., & Cummings, B. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010385 · Cited by 618
Near-infrared luminescence high-contrast in vivo biomedical imaging
Chen, Y., Wang, S., & Zhang, F. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00002-8 · Cited by 615
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 641
Vankayala, R., & Hwang, K. C. (2018) · Advanced Materials · doi:10.1002/adma.201706320 · Cited by 557
Toll-like receptors activation, signaling, and targeting: an overview
El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. E. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0227-2 · Cited by 603
Nanoparticle-based drug delivery systems for cancer therapy
Dang, Y., & Guan, J. (2020) · Smart Materials in Medicine · doi:10.1016/j.smaim.2020.04.001 · Cited by 574
“Researchers have reported that nanoparticles with a diameter of 50–100 nm have a higher accumulation in liver, spleen, and lung [64,65], leading to nonspecific accumulation of nanoparticles.”
BackgroundRecent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy
Ji, B., Wei, M., & Yang, B. (2021) · Theranostics · doi:10.7150/thno.67300 · Cited by 563
“In biological systems, the change in the behavior of a biomacromolecule is often a result of its response to a combination of multiple environmental changes [105].”
BackgroundLi, H.-J., Du, J.-Z., Liu, J., Du, X.-J., Shen, S., Zhu, Y.-H., Wang, X., Ye, X., Nie, S., & Wang, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b02326 · Cited by 537
Strategies to improve micelle stability for drug delivery
Lu, Y., Zhang, E., Yang, J., & Cao, Z. (2018) · Nano Research · doi:10.1007/s12274-018-2152-3 · Cited by 530
“The result can be an unfavorable drug biodistribution and a therapeutic outcome that is similar to that of an unprotected (non-encapsulated) drug [38].”
Shahbazi, M., Faghfouri, L., Ferreira, M. P. A., Figueiredo, P., Maleki, H. H., Sefat, F., Hirvonen, J. J., & Santos, H. A. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00283a · Cited by 533
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Zhang, L., Liao, Y., & Tang, L. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1059-5 · Cited by 514
“In addition, some other unexpected side effects may come up, such as the accumulation of therapeutic miRNAs at healthy tissues because of the conjunction of serum proteins on the surface of nano-vectors, the breakdown of nanoparticles on the account of the shearing stress which from the flowing blood, the unsuccessful…”
BackgroundEngineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet‐Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 537
Nanoparticle Characterization: What to Measure?
Modena, M. M., Rühle, B., Burg, T. P., & Wuttke, S. (2019) · Advanced Materials · doi:10.1002/adma.201901556 · Cited by 537
A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications
Casalini, T., Rossi, F., Castrovinci, A., & Perale, G. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00259 · Cited by 500
“Other strategies involve surface functionalization with ad hoc peptides that delay phagocytic clearance (Rodriguez et al., 2013), or coating with cell membranes from red blood cells or leukocytes (Blanco et al., 2015).”
BackgroundPeptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 504
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 537
Native and bioengineered extracellular vesicles for cardiovascular therapeutics
de Abreu, R. C., Fernandes, H., Martins, P. A. D. C., Sahoo, S., Emanueli, C., & Ferreira, L. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0389-5 · Cited by 509
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 513
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Application of Radiosensitizers in Cancer Radiotherapy
Gong, L., Zhang, Y., Liu, C., Zhang, M., & Han, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290438 · Cited by 484
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Size‐Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting
Kang, H., Rho, S., Stiles, W. R., Hu, S., Baek, Y., Hwang, D. W., Kashiwagi, S., Kim, M. S., & Choi, H. S. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901223 · Cited by 495
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Engineered exosomes from different sources for cancer-targeted therapy
Zhang, M. H., Hu, S., Liu, L., Dang, P., Liu, Y., Sun, Z., Qiao, B., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01382-y · Cited by 493
“Despite the pronounced antitumor effects of natural ACNVs, the macropinocytosis of mononuclear phagocyte system (MPS), including in the liver and spleen, results in the quick clearance of exosomes in bloodstream and minimal accumulation within tumor area.(24) Therefore, researchers decorated ACNVs with distearoyl phos…”
BackgroundSize and surface charge characterization of nanoparticles with a salt gradient
Rasmussen, M. K., Pedersen, J. N., & Marie, R. (2020) · Nature Communications · doi:10.1038/s41467-020-15889-3 · Cited by 492
Li, J., Rao, J., & Pu, K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.025 · Cited by 472
“The potential utility of nanoparticles as delivery vehicles for therapeutic agents has been demonstrated [6-9].”
BackgroundEffects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 477
Biomimetic proteolipid vesicles for targeting inflamed tissues
Molinaro, R., Corbo, C., Martinez, J. O., Taraballi, F., Evangelopoulos, M., Minardi, S., Yazdi, I. K., Zhao, P., Rosa, E. D., Sherman, M. B., et al. (2016) · Nature Materials · doi:10.1038/nmat4644 · Cited by 459
DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury
Jiang, D., Ge, Z., Im, H., England, C. G., Ni, D., Hou, J., Zhang, L., Kutyreff, C. J., Yan, Y., Liu, Y., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0317-8 · Cited by 450
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 458
Yao, C., Wang, W., Wang, P., Zhao, M., Li, X., & Zhang, F. (2018) · Advanced Materials · doi:10.1002/adma.201704833 · Cited by 448
Engineering microrobots for targeted cancer therapies from a medical perspective
Schmidt, C. K., Medina‐Sánchez, M., Edmondson, R. J., & Schmidt, O. G. (2020) · Nature Communications · doi:10.1038/s41467-020-19322-7 · Cited by 452
Layered double hydroxide-based nanomaterials for biomedical applications
Hu, T., Gu, Z., Williams, G. R., Štrimaite, M., Zha, J., Zhou, Z., Zhang, X., Tan, C., & Liang, R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00236a · Cited by 449
Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies
Ding, S., Khan, A. I., Cai, X., Song, Y., Lyu, Z., Du, D., Dutta, P., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.02.001 · Cited by 468
Obstacles and opportunities in a forward vision for cancer nanomedicine
de Lázaro, I., & Mooney, D. J. (2021) · Nature Materials · doi:10.1038/s41563-021-01047-7 · Cited by 447
MicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 455
“To overcome these barriers, miRNA-loaded nanoparticles (NPs) have been proposed [21–23], by virtue of NPs ability to shield the loaded agent from the external environment, thereby reducing inactivation or degradation, and enhancing circulation time and targeted accumulation [24].”
BackgroundAn, F., & Zhang, X. (2017) · Theranostics · doi:10.7150/thno.19365 · Cited by 437
“In order to improve the drug delivery efficiency with these nanoparticles, it is necessary to stabilize these nanoparticles with additional materials [201].”
BackgroundEl‐Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El‐Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 436
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
